Katharine L. Lewis

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

Anthony R. Mato, Nirav N. Shah, Wojciech Jurczak et al. · The Lancet · 2021 · 432 citations · Full text

Phase 1/2, Lymphoid Neoplasia, Medicine +6

Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance

Piers Blombery, Ella R. Thompson, Thomas E. Lew et al. · Blood Advances · 2022 · 89 citations · Full text

Hematological Malignancy, Btk Leu528trp Mutation, Oncology +15

Six-Minute Walk, Maximal Exercise Tests: Reproducibility in Fibrotic Interstitial Pneumonia

Katharine L. Lewis · Yearbook of Pulmonary Disease · 2006 · 52 citations

Physical Activity, Kinesiology, Exercise +10

Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience

Katharine L. Lewis, Collin K. Chin, Kate Manos et al. · British Journal of Haematology · 2020 · 48 citations · Full text

New Directions for Mantle Cell Lymphoma in 2022

Anita Kumar, Toby A. Eyre, Katharine L. Lewis et al. · American Society of Clinical Oncology Educational Book · 2022 · 48 citations